INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Observational study / 2002

Elevated plasma homocysteine levels were linked to an increased risk of newly diagnosed dementia and Alzheimer's disease.

In the Framingham Study, researchers examined whether plasma total homocysteine levels at baseline and eight years prior related to the risk of incident dementia in 1,092 dementia-free participants. Over a median follow-up of eight years, 111 subjects developed dementia, including 83 with Alzheimer's disease. The multivariable-adjusted relative risk of dementia was 1.4 (95% CI, 1.1 to 1.9) for each 1 SD increase in log-transformed homocysteine at baseline or eight years earlier. The relative risk of Alzheimer's disease was 1.8 (95% CI, 1.3 to 2.5) per 1 SD increase at baseline and 1.6 (95% CI, 1.2 to 2.1) per 1 SD increase eight years prior; risk nearly doubled with levels above 14 micromol per liter.

Shows an association, not proof of cause and effect.

Study type
Prospective cohort study
Who was studied
1,092 subjects without dementia (667 women, 425 men; mean age 76 years) from the Framingham Study
What was measured
Newly diagnosed dementia and Alzheimer's disease over follow-up

THE PAPER

Plasma homocysteine as a risk factor for dementia and Alzheimer's disease.

Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA. N Engl J Med, 2002.

PubMed 11844848 ↗DOI 10.1056/nejmoa011613 ↗

Nutrients & adequacyBrain & moodHealthy aging & longevity

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.